Save your place

Sign in to WhoBought

Please try again later.

Arbutus Biopharma Corporation (ABUS) institutional ownership

Latest close $4.33 Jul 22, 2026
Market cap$626M 52-week range SectorHealthcare
Funds holding · Q1 2026
148
reported ABUS position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
70 buyers · 78 sellers

Arbutus Biopharma Corporation (ABUS) price and institutional activity

Dates

Q1 2026

$0 bought by 70 investors
Two Seas Capital LPRubric Capital Management LP +68 more
$0 sold by 78 investors
Adar1 Capital Management, LLCAdage Capital Partners Gp, L.L.C. +76 more
Bought Sold Totals per quarter; hover a bar for the names.

Arbutus Biopharma Corporation (ABUS) institutional activity · 78

Investor Type Est. change Change Δ Own Date
Adar1 Capital Management, LLC · Reduced
Change −2.3M Date Q1 2026
Adar1 Capital Management, LLC Reduced· Q1 2026 −2.3M Q1 2026
Adage Capital Partners Gp, L.L.C. · Reduced
Change −1.7M Date Q1 2026
Adage Capital Partners Gp, L.L.C. Reduced· Q1 2026 −1.7M Q1 2026
Stempoint Capital LP · Exited
Change −987K Δ Own −100.0% Date Q1 2026
Stempoint Capital LP Exited· Q1 2026 −987K −100.0% Q1 2026
Morgan Stanley · Reduced
Change −811K Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −811K Q1 2026
Saba Capital Management, L.P. · Exited
Change −348K Δ Own −100.0% Date Q1 2026
Saba Capital Management, L.P. Exited· Q1 2026 −348K −100.0% Q1 2026
Rangeley Capital, LLC · Reduced
Change −340K Date Q1 2026
Rangeley Capital, LLC Reduced· Q1 2026 −340K Q1 2026
Hudson Bay Capital Management LP · Reduced
Change −325K Date Q1 2026
Hudson Bay Capital Management LP Reduced· Q1 2026 −325K Q1 2026
Murchinson Ltd. · Exited
Change −275K Δ Own −100.0% Date Q1 2026
Murchinson Ltd. Exited· Q1 2026 −275K −100.0% Q1 2026
Woodline Partners LP · Reduced
Change −176K Date Q1 2026
Woodline Partners LP Reduced· Q1 2026 −176K Q1 2026
Schwab · Reduced
Change −161K Date Q1 2026
Schwab Reduced· Q1 2026 −161K Q1 2026
Qube Research & Technologies Ltd · Exited
Change −158K Δ Own −100.0% Date Q1 2026
Qube Research & Technologies Ltd Exited· Q1 2026 −158K −100.0% Q1 2026
Bank of America Corp · Reduced
Change −149K Date Q1 2026
Bank of America Corp Reduced· Q1 2026 −149K Q1 2026
Man Group PLC · Exited
Change −121K Δ Own −100.0% Date Q1 2026
Man Group PLC Exited· Q1 2026 −121K −100.0% Q1 2026
Kennedy Capital Management LLC · Reduced
Change −112K Date Q1 2026
Kennedy Capital Management LLC Reduced· Q1 2026 −112K Q1 2026
Wells Fargo & Company · Reduced
Change −108K Date Q1 2026
Wells Fargo & Company Reduced· Q1 2026 −108K Q1 2026
Data through Q1 2026 · filed Jun 2, 2026
15 of 78

Famous investor activity in Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Corporation (ABUS) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Sawhney Roger · Director Grant (A) 79K
Owned 79K Trade date Jun 8, 2026 Filed date Jun 10, 2026
Sawhney Roger Director Grant (A) 79K 79K Jun 8, 2026 Jun 10, 2026
Beardsley Robert A. · Director Grant (A) 79K
Owned 79K Trade date Jun 8, 2026 Filed date Jun 10, 2026
Beardsley Robert A. Director Grant (A) 79K 79K Jun 8, 2026 Jun 10, 2026
Nguyen Tuan · CFO 2 operations 262K
Owned 188K Trade date Feb 2, 2026 Filed date Feb 2, 2026
Nguyen Tuan CFO 2 operations 262K 188K Feb 2, 2026 Feb 2, 2026
Androski Lindsay · Director 2 operations 100K
Owned 72K Trade date Feb 2, 2026 Filed date Feb 2, 2026
Androski Lindsay Director 2 operations 100K 72K Feb 2, 2026 Feb 2, 2026
Sawhney Roger · Director Grant (A) 158K
Owned 158K Trade date Aug 4, 2025 Filed date Aug 6, 2025
Sawhney Roger Director Grant (A) 158K 158K Aug 4, 2025 Aug 6, 2025
5 of 5

Arbutus Biopharma Corporation (ABUS) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Roivant Sciences Ltd. 38.8M
% of shares outstanding 29.1% Filing date Oct 20, 2021
Roivant Sciences Ltd. 38.8M 29.1% Oct 20, 2021
Morgan Stanley 19.4M
% of shares outstanding 10.3% Filing date Jun 10, 2024
Morgan Stanley 19.4M 10.3% Jun 10, 2024
Two Seas Capital LP 18.6M
% of shares outstanding 9.4% Filing date May 15, 2026
Two Seas Capital LP 18.6M 9.4% May 15, 2026
Whitefort Capital Management, LP 15.8M
% of shares outstanding 8.0% Filing date Apr 28, 2026
Whitefort Capital Management, LP 15.8M 8.0% Apr 28, 2026
BlackRock Inc. 10.4M
% of shares outstanding 6.2% Filing date Feb 12, 2024
BlackRock Inc. 10.4M 6.2% Feb 12, 2024
Two Seas Capital LP 8.4M
% of shares outstanding 4.4% Filing date Nov 14, 2024
Two Seas Capital LP 8.4M 4.4% Nov 14, 2024
Rtw Investments, LP 2.5M
% of shares outstanding 1.7% Filing date Feb 14, 2022
Rtw Investments, LP 2.5M 1.7% Feb 14, 2022
7 of 7

Arbutus Biopharma Corporation (ABUS) ownership FAQ

Who owns ABUS?

148 reporting institutions disclosed ABUS position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.